ライフサイエンスコーパス: esophageal carcinoma

1 ecimens (seven Barrett's metaplasias and six esophageal carcinomas).

2 r, in development of Barrett's esophagus and esophageal carcinoma.

3 atients undergoing nonoperative treatment of esophageal carcinoma.

4 ion does not alter the TNM classification of esophageal carcinoma.

5 of 171 patients identified, 2 had died from esophageal carcinoma.

6 reasingly used in treatment of patients with esophageal carcinoma.

7 ) for intramucosal (T1a) or submucosal (T1b) esophageal carcinoma.

8 ificantly improved survival in patients with esophageal carcinoma.

9 ging and impacts on therapy of patients with esophageal carcinoma.

10 mor types, including breast, pancreatic, and esophageal carcinoma.

11 diation followed by surgery in patients with esophageal carcinoma.

12 nd p53 mutations in patients with late-stage esophageal carcinoma.

13 y influence further follow-up guidelines for esophageal carcinoma.

14 atocellular carcinoma, and one SF complex in esophageal carcinoma.

15 ions were examined in two main histotypes of esophageal carcinomas.

16 and confers treatment resistance in lung and esophageal carcinomas.

17 eal cancer-derived cell lines and in primary esophageal carcinomas.

18 tissue tumors (20%), osteosarcomas (16%) and esophageal carcinomas (13%).

19 4 Barrett's esophagus (BA) metaplasias and 8 esophageal carcinomas (3 squamous cell carcinomas and 5

20 Oral-esophageal carcinomas, a model system to investigate mol

21 ients undergoing elective surgery for either esophageal carcinoma (adenocarcinoma or squamous cell ca

22 o-species (human and canine) and two-cancer (esophageal carcinoma and B-cell lymphoma) analysis of sp

23 ceptor (EGFR) is frequently overexpressed in esophageal carcinoma and its precursor lesions.

24 tecan had significant activity in metastatic esophageal carcinoma and resulted in significant relief

25 nd EUS FNA for preoperative nodal staging of esophageal carcinoma and to measure the impact of each s

26 ate that 15-LOX-1 is down-regulated in human esophageal carcinomas and that NSAIDs induce apoptosis i

27 s an important new agent in the treatment of esophageal carcinoma, and further evaluation of this age

28 rative chemoradiation, long-term outcomes of esophageal carcinoma are best predicted utilizing histol

29 ithelium, including lung, head and neck, and esophageal carcinomas, are the leading causes of cancer-

30 of a 5.4 cM region at 7q31-q35 in 43 primary esophageal carcinomas, as well as mutational analyses of

31 at: (a) 15-LOX-1 was down-regulated in human esophageal carcinomas; (b) NSAIDs induced 15-LOX-1 expre

32 rigin or progression of at least a subset of esophageal carcinomas, but that ST7 is not the target ge

33 hat could be used for hospital comparison in esophageal carcinoma care.

34 However, in six of nine esophageal carcinoma cell lines, no FHIT RT-PCR product

35 Squamous carcinoma of the head and neck and esophageal carcinoma demonstrate avid (18)F-FDG uptake.

36 one for patients with potentially resectable esophageal carcinoma did not demonstrate a statistically

37 ng thresholds in patients with biopsy-proven esophageal carcinoma (differentiation of stage T0 diseas

38 Patients with esophageal carcinoma (EC) who are treated with definitiv

39 Esophageal carcinoma (ESCA) is a leading cause of cancer

40 Esophageal carcinoma has a special place in gastrointest

41 Patients with localized esophageal carcinoma have a 5-year survival rate of less

42 Esophageal carcinomas have high fatality rates, making c

43 s for the treatment of partially obstructive esophageal carcinoma, high-grade dysplasia associated wi

44 leading to its overexpression in breast and esophageal carcinomas; however, the contribution of stab

45 actor for the most important risk factor for esophageal carcinoma (ie, BE).

46 rformance of MRI in determining the stage of esophageal carcinoma in patients before esophagectomy an

47 11, patients with a resectable intrathoracic esophageal carcinoma, including the gastroesophageal jun

48 y therapy for patients with locally advanced esophageal carcinoma is recommended.

49 Therapy of esophageal carcinoma is stage dependent.

50 , the prognosis for patients with inoperable esophageal carcinoma is still poor and the reliability o

51 tt's esophagus with high-grade dysplasia, or esophageal carcinoma limited to the lamina propria.

52 cinomas and dysplasias, gastric cancers, and esophageal carcinomas, manifest microsatellite instabili

53 ), gastric cancer (n = 2), and squamous-cell esophageal carcinoma (n = 1) were retrieved.

54 e development or progression of most primary esophageal carcinomas or UCANs, although lack of express

55 Among esophageal carcinomas RAR-beta mRNA was expressed in 62%

56 Although this is not yet the case for esophageal carcinoma, recent improved chemoradiation reg

57 ith medically inoperable and/or irresectable esophageal carcinoma, referred for dCRT, were randomly a

58 ave sequenced exon 5 of cyclin D1 in primary esophageal carcinoma samples and in cell lines derived f

59 cember 1999 to March 2001, all patients with esophageal carcinoma seen at the Mayo Clinic Rochester w

60 in determining the appropriate management of esophageal carcinoma (squamous cell carcinoma and adenoc

61 gnosed with stage pT3-4Nx-0M0 or pT1-4N1-3M0 esophageal carcinoma (squamous cell or adenocarcinoma) f

62 was diminished in stomach adenocarcinoma and esophageal carcinoma (STAD-ESCA) and completely disappea

63 ican Joint Committee on Cancer, 7th Edition, esophageal carcinoma staging system is derived from pati

64 cer Audit who underwent potentially curative esophageal carcinoma surgery in 2011 to 2018, were inclu

65 In esophageal carcinomas that overexpress cyclin D1, Fbx4 i

66 complex setting of multimodal treatments of esophageal carcinoma; this leads to rather undifferentia

67 schizophrenia and one for the MMP-2 gene and esophageal carcinoma, to evaluate the performance of the

68 cancer, including liver metastasectomy, and esophageal carcinoma treated primarily with chemoradiati

69 y of 43 patients with potentially resectable esophageal carcinoma treated with an intensive regimen o

70 ot for LRC in patients with locally advanced esophageal carcinoma treated with definitive radiochemot

71 A total of 125 patients with esophageal carcinoma were enrolled.

72 One hundred patients with esophageal carcinoma were randomized to receive either s

73 ity but low specificity for the detection of esophageal carcinoma, which shows promise for determinin

74 nd multifocal neoplasia in patients with pT1 esophageal carcinoma who underwent esophagectomy without

75 substantial antitumor activity in metastatic esophageal carcinoma, with a remarkable complete respons